SECURE®-C Cervical Artificial Disc Clinical Study/ SECURE-C Cervical Artificial Disc Postmarket Approval Study

Inclusion Criteria: * Symptomatic cervical disc disease (SCDD) in one vertebral level between C3-C7, defined as neck or arm (radicular) pain, or functional or neurological deficit and radiographic confirmation (by CT, MRI, X-ray, etc.) of any of the following: * Herniated nucleus pulposus; * Radiculopathy or myelopathy; * Spondylosis (defined by the presence of osteophytes); or * Loss of disc height. * Age between 18 and 60 years * Failed at least 6 weeks of conservative treatment * Neck Disability Index (NDI) Questionnaire score of at least 30 (as percentage of 50 point total) * Able to understand and sign informed consent form * Psychosocially, mentally and physically able to fully comply with this protocol including adhering to follow-up schedule and filling out forms * Able to meet the proposed follow-up schedule at 6 weeks, 3 months, 6 months, 12 months and 24 months * Able to follow postoperative management program Exclusion Criteria: * More than one vertebral level requiring treatment * Prior fusion surgery adjacent to the vertebral level being treated * Prior surgery at the level to be treated * Clinically compromised vertebral bodies at the affected level(s) due to current or past trauma * Radiographic confirmation of facet joint disease or degeneration, defined as apparent sclerosis and/or hypertrophy of the facets demonstrated on AP radiographs as a disruption of the normally smooth facet curve * Marked cervical instability on resting lateral or flexion/extension radiographs: * Translation greater than 3mm, and/or * More than 11° of rotational difference from that of either adjacent level. * Severe spondylosis at the level to be treated as characterized by any of the following: * Bridging osteophytes; * A loss of disc height greater than 50%; or * Absence of motion (\<2°) * Neck or arm pain of unknown etiology * Osteoporosis, osteopenia, Paget's disease, osteomalacia or any other metabolic bone disease * Pregnant or interested in becoming pregnant in the next 2 years * Active systemic or local infection * Known allergy to titanium, polyethylene, cobalt, chromium or molybdenum * Taking medications or any drug known to potentially interfere with bone/soft tissue healing (e.g., steroids) * Rheumatoid arthritis or other autoimmune disease * Systemic disease including AIDS, HIV, Hepatitis * Active malignancy: A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there has been no clinical signs or symptoms of the malignancy for at least 5 years * Neuromuscular disorders such as muscular dystrophy, spinal muscular atrophy, amyotrophic lateral sclerosis, etc. * Acute mental illness or substance abuse * Use of bone growth stimulator within past 30 days * Participation in other investigational device or drug clinical trials within 30 days of surgery * Prisoners